NEW ORLEANS, LA – A big congratulations to Dr. Patrick Dennis and his outstanding site team for randomizing the first U.S. patient in a Phase 3 clinical trial for osteoarthritis of the knee!

This important milestone reflects not only the strength of Dr. Dennis’s leadership but also the exceptional coordination, preparedness, and patient-centered care demonstrated by his entire team. Randomizing the first patient in a large-scale, late-phase trial is no small achievement—it requires efficient site activation, robust community engagement, and a deep understanding of study protocol and patient eligibility. We are proud to recognize this moment as a testament to the operational excellence and clinical expertise that Dr. Dennis consistently brings to the table.

As a long-standing research partner with DelRicht Research, Dr. Dennis has conducted more than 100 trials, many of which focus on chronic pain and musculoskeletal conditions. His reputation as a trusted investigator stems from his dedication to both scientific rigor and patient advocacy. In every study, his goal remains the same: to help move the science forward while improving the quality of life for individuals affected by debilitating conditions like osteoarthritis.

Osteoarthritis of the knee affects millions of people across the U.S., limiting mobility, independence, and daily functioning. By participating in this pivotal trial, Dr. Dennis and his team are playing a key role in evaluating new therapeutic options that have the potential to change the standard of care.

We’re grateful for Dr. Patrick Dennis’s continued partnership and for the passion he brings to advancing medical research. Congratulations again to Dr. Dennis and his team. We look forward to following the progress of this important study and the hope it brings to patients in need.

Learn more about our work in osteoarthritis research at DelRicht Research.